Methods
Our study concentrated on analyzing the information collected from a
prospectively observational registry of AF ablation procedures conducted
at our institution, which has been documented in the Chinese Clinical
Trial Registry (ChiCTR-OCH-14004674)15. The research
received approval from the local Institutional Review Board, ensuring
that all study participants provided written informed consent. The
primary objective of the study was to assess two key outcomes: the
recurrence rate of AF and the incidence of MACCE, which include stroke,
TIAs, systemic embolic events, acute myocardial infarction, advanced
heart failure, and mortality. We also tracked significant bleeding
episodes and instances of patient hospital readmission. Study inclusion
criteria mandated that participants must have undergone an AF catheter
ablation at our institution between January 2015 and December 2020.
Exclusions applied to those who were: (i) below 18 years of age, (ii)
monitored for less than a one-year period post-ablation, or (iii)
diagnosed with mitral valvular heart disease. Baseline demographic
information, physical metrics including height and weight, medical
histories, alcohol use patterns, and echocardiographic data were
meticulously gathered and arranged. In line with contemporary protocols,
we computed the CHA2DS2-VASc and
HAS-BLED scores for each participant16.